| Libo Feng,Dong Xia,Yu Liu,Xiaolong Chen. SMARCC1 number variation is related to metastatic colon cancer: an investigation based on TCGA data. Oncol Transl Med, 2021, 7: 216-220. |
| SMARCC1 number variation is related to metastatic colon cancer: an investigation based on TCGA data |
| Received:September 19, 2021 Revised:October 22, 2021 |
| View Full Text View/Add Comment Download reader |
| KeyWord:colon cancer (CC); copy number variation (CNV); genetic marker |
| Author Name | Affiliation | E-mail | | Libo Feng | The Affiliated Hospital of Southwest Medical University | f125058197@163.com | | Dong Xia | The Affiliated Hospital of Southwest Medical University | | | Yu Liu | Department of Electrocardiogram, Affiliated Hospital of Southwest Medical University, Luzhou 646000, China | | | Xiaolong Chen | The Affiliated Hospital of Southwest Medical University | 1870747218@qq.com |
|
| Hits: 3083 |
| Download times: 3329 |
| Abstract: |
| Objective There are no well-defined genetic indicators for distant metastatic illness in patients with colon
cancer (CC). The discovery of genetic changes linked to metastatic CC might aid in the development of
systemic and local therapeutic approaches. Using The Cancer Genome Atlas (TCGA), we examined the
relationship between copy number variation (CNV) of SWI/SNF-related matrix-associated actin-dependent
regulator of chromatin subfamily C member 1 (SMARCC1) and distant metastatic illness in patients with CC.
Methods Genetic sequencing data of all relevant CC patients and clinical features were collected from
TCGA using R. There were 506 CC patients with CNV and clinical outcome data. The CNV of SMARCC1
was examined for its correlation with distant metastatic disease using the TCGA CC dataset (M1 vs. M0).
After adjusting for age, sex, T stage, N stage, adjuvant chemotherapy, microsatellite instability (MSI), and
surgical margin status, univariate and multivariate logistic regression analyses were performed.
Results SMARCC1 CNV was linked to distant metastatic disease (P = 0.012 and 0.008 in univariate
and multivariate analysis, respectively); positive lymph nodes and margin status were also associated with
distal metastases (all P < 0.01). MSI, T stage, N stage, adjuvant treatment, sex, race, and MSI were not
associated with metastases (all P > 0.05).
Conclusion SMARCC1 CNV is associated with distant metastatic disease in patients with CC. In
individuals with CC, such genetic profiles might be utilized therapeutically to support optimal systemic
treatment options against local treatments for CC, such as radiation therapy, pending additional confirmation. |
| Close |
|
|
|